These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 19589050)

  • 41. Effects of antiglucocorticoid treatment on 5-HT1A function in depressed patients and healthy subjects.
    Price LH; Cappiello A; Malison RT; McDougle CJ; Pelton GH; Schöllnhammer G; Heninger GR
    Neuropsychopharmacology; 1997 Oct; 17(4):246-57. PubMed ID: 9326749
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The combined dexamethasone/CRH test as a potential surrogate marker in depression.
    Ising M; Künzel HE; Binder EB; Nickel T; Modell S; Holsboer F
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1085-93. PubMed ID: 15950349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Dehydroepiandrosteron (DHEA) in the mechanisms of stress and depression].
    Załuska M; Janota B
    Psychiatr Pol; 2009; 43(3):263-74. PubMed ID: 19725420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulation of the hypothalamic-pituitary-adrenal axis.
    Papadimitriou A; Priftis KN
    Neuroimmunomodulation; 2009; 16(5):265-71. PubMed ID: 19571587
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vasopressin V1B Receptor Antagonists as Potential Antidepressants.
    Chaki S
    Int J Neuropsychopharmacol; 2021 Jul; 24(6):450-463. PubMed ID: 33733667
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peony glycosides produce antidepressant-like action in mice exposed to chronic unpredictable mild stress: effects on hypothalamic-pituitary-adrenal function and brain-derived neurotrophic factor.
    Mao QQ; Ip SP; Ko KM; Tsai SH; Che CT
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1211-6. PubMed ID: 19596036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of antidepressants in the treatment of abdominal obesity.
    Rosmond R; Björntorp P
    Med Hypotheses; 2000 Jun; 54(6):990-4. PubMed ID: 10867753
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial.
    Katz DA; Locke C; Greco N; Liu W; Tracy KA
    Brain Behav; 2017 Mar; 7(3):e00628. PubMed ID: 28293470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mifepristone as a therapeutic agent in psychiatry.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2013 Jun; 51(6):11-4. PubMed ID: 23814820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The glucocorticoid receptor: part of the solution or part of the problem?
    Pariante CM
    J Psychopharmacol; 2006 Jul; 20(4 Suppl):79-84. PubMed ID: 16785275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypothalamic-pituitary-adrenal (HPA) axis functioning as predictor of antidepressant response-Meta-analysis.
    Fischer S; Macare C; Cleare AJ
    Neurosci Biobehav Rev; 2017 Dec; 83():200-211. PubMed ID: 29032090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targets of anti-glucocorticoid therapy for stress-related diseases.
    Martocchia A; Stefanelli M; Falaschi GM; Toussan L; Rocchietti March M; Raja S; Romano G; Falaschi P
    Recent Pat CNS Drug Discov; 2013 Apr; 8(1):79-87. PubMed ID: 23489288
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and biological effects of mifepristone treatment for psychotic depression.
    Flores BH; Kenna H; Keller J; Solvason HB; Schatzberg AF
    Neuropsychopharmacology; 2006 Mar; 31(3):628-36. PubMed ID: 16160710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning.
    Spijker AT; van Rossum EF
    Ann N Y Acad Sci; 2009 Oct; 1179():199-215. PubMed ID: 19906241
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Advances in the molecular treatment of depression].
    Páez X; Hernández L; Baptista T
    Rev Neurol; 2003 Sep 1-15; 37(5):459-70. PubMed ID: 14533097
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucocorticoid receptor transgenic mice as models for depression.
    Chourbaji S; Gass P
    Brain Res Rev; 2008 Mar; 57(2):554-60. PubMed ID: 17524489
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel agents in development for the treatment of depression.
    Grady MM; Stahl SM
    CNS Spectr; 2013 Dec; 18 Suppl 1():37-40; quiz 41. PubMed ID: 24252548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression.
    Barden N
    J Psychiatry Neurosci; 2004 May; 29(3):185-93. PubMed ID: 15173895
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression.
    Watson S; Gallagher P; Porter RJ; Smith MS; Herron LJ; Bulmer S; ; Young AH; Ferrier IN
    Biol Psychiatry; 2012 Dec; 72(11):943-9. PubMed ID: 22770649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The importance of the hypothalamo-pituitary-adrenal axis as a therapeutic target in anorexia nervosa.
    Bou Khalil R; Souaiby L; Farès N
    Physiol Behav; 2017 Mar; 171():13-20. PubMed ID: 28043861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.